Drug Patents owned by Arbor Pharms Llc

1. Drug name - CETYLEV

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9561204 ARBOR PHARMS LLC Effervescent compositions containing N-acetylcysteine May, 2032

(9 years from now)

US8747894 ARBOR PHARMS LLC Effervescent compositions containing N-acetylcysteine May, 2032

(9 years from now)

US9427421 ARBOR PHARMS LLC Effervescent compositions containing N-acetylcysteine May, 2032

(9 years from now)

Drugs and Companies using ACETYLCYSTEINE ingredient

Treatment: Method of treating acetaminophen overdose with acetylcysteine solutions

Dosage: TABLET, EFFERVESCENT;ORAL

More Information on Dosage
Strength Dosage Availability
2.5GM TABLET, EFFERVESCENT;ORAL Discontinued
500MG TABLET, EFFERVESCENT;ORAL Discontinued

2. Drug name - EDARBI

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US7157584 ARBOR PHARMS LLC Benzimidazole derivative and use thereof
May, 2025

(2 years from now)

CN101381366A ARBOR PHARMS LLC Benzimidazole Derivative And Use As Aii Receptor Antagonist
Feb, 2025

(2 years from now)

CN101381366B ARBOR PHARMS LLC Benzimidazole Derivatives And Their Pharmaceutical Use
Feb, 2025

(2 years from now)

CN1946717A ARBOR PHARMS LLC Benzimidazole Derivative And Its Use
Feb, 2025

(2 years from now)

CN100503605C ARBOR PHARMS LLC Benzimidazole Derivatives And Their Use As A Ii Receptor Antagonists
Feb, 2025

(2 years from now)

IN242537B ARBOR PHARMS LLC Benzimidazole Derivative And A Process For The Preparation Thereof
Feb, 2025

(2 years from now)

IN200602785P2 ARBOR PHARMS LLC Benzimidazole Derivative And Use Thereof
Feb, 2025

(2 years from now)

EP2119715A1 ARBOR PHARMS LLC Benzimidazole Derivative And Its Use As Aii Receptor Antagonist
Feb, 2025

(2 years from now)

EP2119715B1 ARBOR PHARMS LLC Benzimidazole Derivative And Its Use As Aii Receptor Antagonist
Feb, 2025

(2 years from now)

EP1857457A3 ARBOR PHARMS LLC Benzimidazole Derivative And Its Use As Aii Receptor Antagonist
Feb, 2025

(2 years from now)

EP1857457B1 ARBOR PHARMS LLC Benzimidazole Derivative And Its Use As Aii Receptor Antagonist
Feb, 2025

(2 years from now)

EP1857457A2 ARBOR PHARMS LLC Benzimidazole Derivative And Its Use As Aii Receptor Antagonist
Feb, 2025

(2 years from now)

EP1718641A2 ARBOR PHARMS LLC Benzimidazole Derivative And Its Use As A Ii Receptor Antagonist
Dec, 2026

(4 years from now)

EP1718641B1 ARBOR PHARMS LLC Benzimidazole Derivative And Its Use As A Ii Receptor Antagonist
Dec, 2026

(4 years from now)

These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US7572920 ARBOR PHARMS LLC Benzimidazole derivative and use as a II receptor antagonist Jan, 2025

(2 years from now)

US9066936 ARBOR PHARMS LLC Solid pharmaceutical composition comprising a benzimidazole-7-carboxylate derivative and a pH control agent Mar, 2028

(5 years from now)

Drugs and Companies using AZILSARTAN KAMEDOXOMIL ingredient

Treatment: Treatment of hypertension

Dosage: TABLET;ORAL

More Information on Dosage
Strength Dosage Availability
EQ 40MG MEDOXOMIL TABLET;ORAL Prescription
EQ 80MG MEDOXOMIL TABLET;ORAL Prescription

3. Drug name - EDARBYCLOR

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US7157584 ARBOR PHARMS LLC Benzimidazole derivative and use thereof
May, 2025

(2 years from now)

CN101381366A ARBOR PHARMS LLC Benzimidazole Derivative And Use As Aii Receptor Antagonist
Feb, 2025

(2 years from now)

CN101381366B ARBOR PHARMS LLC Benzimidazole Derivatives And Their Pharmaceutical Use
Feb, 2025

(2 years from now)

CN1946717A ARBOR PHARMS LLC Benzimidazole Derivative And Its Use
Feb, 2025

(2 years from now)

CN100503605C ARBOR PHARMS LLC Benzimidazole Derivatives And Their Use As A Ii Receptor Antagonists
Feb, 2025

(2 years from now)

IN242537B ARBOR PHARMS LLC Benzimidazole Derivative And A Process For The Preparation Thereof
Feb, 2025

(2 years from now)

IN200602785P2 ARBOR PHARMS LLC Benzimidazole Derivative And Use Thereof
Feb, 2025

(2 years from now)

EP2119715A1 ARBOR PHARMS LLC Benzimidazole Derivative And Its Use As Aii Receptor Antagonist
Feb, 2025

(2 years from now)

EP2119715B1 ARBOR PHARMS LLC Benzimidazole Derivative And Its Use As Aii Receptor Antagonist
Feb, 2025

(2 years from now)

EP1857457A3 ARBOR PHARMS LLC Benzimidazole Derivative And Its Use As Aii Receptor Antagonist
Feb, 2025

(2 years from now)

EP1857457B1 ARBOR PHARMS LLC Benzimidazole Derivative And Its Use As Aii Receptor Antagonist
Feb, 2025

(2 years from now)

EP1857457A2 ARBOR PHARMS LLC Benzimidazole Derivative And Its Use As Aii Receptor Antagonist
Feb, 2025

(2 years from now)

EP1718641A2 ARBOR PHARMS LLC Benzimidazole Derivative And Its Use As A Ii Receptor Antagonist
Dec, 2026

(4 years from now)

EP1718641B1 ARBOR PHARMS LLC Benzimidazole Derivative And Its Use As A Ii Receptor Antagonist
Dec, 2026

(4 years from now)

These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US7572920 ARBOR PHARMS LLC Benzimidazole derivative and use as a II receptor antagonist Jan, 2025

(2 years from now)

US9066936 ARBOR PHARMS LLC Solid pharmaceutical composition comprising a benzimidazole-7-carboxylate derivative and a pH control agent Mar, 2028

(5 years from now)

US9169238 ARBOR PHARMS LLC Solid pharmaceutical composition Feb, 2030

(7 years from now)

US9387249 ARBOR PHARMS LLC Methods of treating hypertension with at least one angiotensin II receptor blocker and chlorthalidone Jul, 2031

(8 years from now)

Drugs and Companies using AZILSARTAN KAMEDOXOMIL; CHLORTHALIDONE ingredient

Treatment: Treatment of hypertension

Dosage: TABLET;ORAL

More Information on Dosage
Strength Dosage Availability
EQ 40MG MEDOXOMIL;12.5MG TABLET;ORAL Prescription
EQ 40MG MEDOXOMIL;25MG TABLET;ORAL Prescription

4. Drug name - EVEKEO ODT

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10130580 ARBOR PHARMS LLC Taste-masked pharmaceutical compositions Apr, 2024

(1 year, 6 months from now)

US11160772 ARBOR PHARMS LLC Oral amphetamine composition Mar, 2037

(14 years from now)

US10441554 ARBOR PHARMS LLC Oral amphetamine composition Mar, 2037

(14 years from now)

Drugs and Companies using AMPHETAMINE SULFATE ingredient

Treatment: NA

Dosage: TABLET, ORALLY DISINTEGRATING;ORAL

More Information on Dosage
Strength Dosage Availability
2.5MG TABLET, ORALLY DISINTEGRATING;ORAL Discontinued
5MG TABLET, ORALLY DISINTEGRATING;ORAL Prescription
10MG TABLET, ORALLY DISINTEGRATING;ORAL Prescription
15MG TABLET, ORALLY DISINTEGRATING;ORAL Prescription
20MG TABLET, ORALLY DISINTEGRATING;ORAL Prescription

5. Drug name - HORIZANT

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US8048917 ARBOR PHARMS LLC Prodrugs of GABA analogs, compositions and uses thereof
Nov, 2022

(a month from now)

US6818787 ARBOR PHARMS LLC Prodrugs of GABA analogs, compositions and uses thereof
Apr, 2025

(2 years from now)

US8026279 ARBOR PHARMS LLC Crystalline form of γ-aminobutyric acid analog
Nov, 2026

(4 years from now)

CN1533270A ARBOR PHARMS LLC Oral Administration Formulation Has Reduced Toxicity Of Prodrugs Of Gaba Analogues
Dec, 2011

(10 years ago)

CN1675165A ARBOR PHARMS LLC Method For Synthesis Of Gaba Analogues Acyloxy Alkyl Derivative
Aug, 2014

(8 years ago)

CN100540526C ARBOR PHARMS LLC Method For The Synthesis Of Gaba Analogue Acyloxy Alkyl Derivative
Aug, 2014

(8 years ago)

CN101381339B ARBOR PHARMS LLC Gaba Analog Prodrug, And Application Of The Composition
Aug, 2016

(6 years ago)

CN101381339A ARBOR PHARMS LLC Prodrugs Of Gaba Analogues, And Uses Of Compositions Thereof
Aug, 2016

(6 years ago)

CN1867322A ARBOR PHARMS LLC Crystalline Form Of -Aminobutyric Acid Analog
Dec, 2017

(4 years ago)

CN1867322B ARBOR PHARMS LLC Crystalline Form Of Gamma-Aminobutyric Acid Analog
Dec, 2017

(4 years ago)

CN1753673B ARBOR PHARMS LLC Prodrug Of Gaba Analogue, Composition And Application Thereof
Jul, 2018

(4 years ago)

CN1753673A ARBOR PHARMS LLC Prodrugs Of Gaba Analogs, And Compositions And Uses Thereof
Jul, 2018

(4 years ago)

CN101434572A ARBOR PHARMS LLC Prodrug Of Gaba Analogue, Composition And Application Thereof
Jun, 2022

(3 months ago)

CN101434572B ARBOR PHARMS LLC Prodrug Of Gaba Analogue, Composition And Application Thereof
Jun, 2022

(3 months ago)

IN200600341P3 ARBOR PHARMS LLC Crystalline Form Of Gamma-Aminobutyric Acid Analog
Oct, 2024

(2 years from now)

IN237299B ARBOR PHARMS LLC Crystalline Form Of Gama-Aminobutyric Acid Analog
Oct, 2024

(2 years from now)

EP1404324B1 ARBOR PHARMS LLC Prodrugs Of Gaba Analogs, Compositions And Uses Thereof
Jun, 2022

(3 months ago)

EP1404324A4 ARBOR PHARMS LLC Prodrugs Of Gaba Analogs, Compositions And Uses Thereof
Jun, 2022

(3 months ago)

EP1404324B2 ARBOR PHARMS LLC Prodrugs Of Gaba Analogs, Compositions And Uses Thereof
Jun, 2022

(3 months ago)

EP1404324A2 ARBOR PHARMS LLC Prodrugs Of Gaba Analogs, Compositions And Uses Thereof
Jun, 2022

(3 months ago)

EP1902714B1 ARBOR PHARMS LLC Prodrugs Of Gaba Analogs, Compositions And Uses Thereof
Jun, 2022

(3 months ago)

EP1902714A1 ARBOR PHARMS LLC Prodrugs Of Gaba Analogs, Compositions And Uses Thereof
Jun, 2022

(3 months ago)

EP2275401A1 ARBOR PHARMS LLC Crystalline 1-{[(Alpha-Isobutanoyloxyethoxy)Carbonyl]Aminomethyl}-1-Cyclohexane Acetic Acid
Jun, 2023

(8 months from now)

EP2275401B1 ARBOR PHARMS LLC Crystalline 1-{[(Alpha-Isobutanoyloxyethoxy)Carbonyl]Aminomethyl}-1-Cyclohexane Acetic Acid
Jun, 2023

(8 months from now)

EP1677767A4 ARBOR PHARMS LLC Crystalline Form Of Gamma-Aminobutyric Acid Analog
Oct, 2024

(2 years from now)

EP1677767B1 ARBOR PHARMS LLC Crystalline Form Of Gamma-Aminobutyric Acid Analog
Oct, 2024

(2 years from now)

EP1677767A2 ARBOR PHARMS LLC Crystalline Form Of Gamma-Aminobutyric Acid Analog
Oct, 2024

(2 years from now)

These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8686034 ARBOR PHARMS LLC Crystalline form of γ-aminobutyric acid analog Jan, 2025

(2 years from now)

US8114909 ARBOR PHARMS LLC Treating or preventing restless legs syndrome using prodrugs of GABA analogs Apr, 2026

(3 years from now)

US8795725 ARBOR PHARMS LLC GABA analog prodrug sustained release oral dosage forms Jun, 2029

(6 years from now)

Drugs and Companies using GABAPENTIN ENACARBIL ingredient

Treatment: Treatment of moderate-to-severe primary restless leg syndrome in adults; management of postherpetic neuralgia (phn) in adults; Treatment of moderate-to-severe primary restless leg syndrome in adults

Dosage: TABLET, EXTENDED RELEASE;ORAL

More Information on Dosage
Strength Dosage Availability
300MG TABLET, EXTENDED RELEASE;ORAL Prescription
600MG TABLET, EXTENDED RELEASE;ORAL Prescription

6. Drug name - NYMALIZE

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US7070581 ARBOR PHARMS LLC Dispenser for medicaments and method and apparatus for making same Jun, 2023

(8 months from now)

US8517997 ARBOR PHARMS LLC Dispenser for medicaments and method and apparatus for making same May, 2024

(1 year, 7 months from now)

US11207306 ARBOR PHARMS LLC Non-aqueous liquid nimodipine compositions Apr, 2038

(15 years from now)

US10576070 ARBOR PHARMS LLC Non-aqueous liquid nimodipine compositions Apr, 2038

(15 years from now)

US10342787 ARBOR PHARMS LLC Non-aqueous liquid nimodipine compositions Apr, 2038

(15 years from now)

Drugs and Companies using NIMODIPINE ingredient

Treatment: A method for the improvement of neurological outcome by reducing the incidence and severity of ischemic deficits in adult patients with subarachnoid hemorrhage (sah) from ruptured intracranial berry aneurysms

Dosage: SOLUTION;ORAL

More Information on Dosage
Strength Dosage Availability
3MG/ML SOLUTION;ORAL Discontinued
6MG/ML SOLUTION;ORAL Prescription

7. Drug name - SOTYLIZE

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10206895 ARBOR PHARMS LLC Sotalol compositions and uses of the same Apr, 2034

(11 years from now)

US11013703 ARBOR PHARMS LLC Sotalol compositions and uses of the same Apr, 2034

(11 years from now)

US9724297 ARBOR PHARMS LLC Sotalol compositions and uses of the same Aug, 2035

(12 years from now)

Drugs and Companies using SOTALOL HYDROCHLORIDE ingredient

Treatment: Sotylize is indicated for the maintenance of normal sinus rhythm [delay in time to recurrence of atrial fibrillation/atrial flutter (afib/afl)] in patients with symptomatic afib/afl who are currently in sinus rhythm; indicated for the treatment of ventricular arrhythmias, such as sustained ventricular tachycardia, that in the judgement of the physician are life-threatening; Sotylize is indicated for the maintenance of normal sinus rhythm [delay in time to recurrence of atrial fibrillation/atrial flutter (afib/afl)] in patients with symptomatic afib/afl who are currently in sinus rhythm

Dosage: SOLUTION;ORAL

More Information on Dosage
Strength Dosage Availability
5MG/ML (5MG/ML) SOLUTION;ORAL Prescription

8. Drug name - TRIPTODUR KIT

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10166181 ARBOR PHARMS LLC Slow release pharmaceutical composition made of microgranules Jun, 2029

(6 years from now)

Drugs and Companies using TRIPTORELIN PAMOATE ingredient

Treatment: NA

Dosage: FOR SUSPENSION, EXTENDED RELEASE;INTRAMUSCULAR

More Information on Dosage
Strength Dosage Availability
EQ 22.5MG BASE/VIAL FOR SUSPENSION, EXTENDED RELEASE;INTRAMUSCULAR Prescription

availability in other generic markets.

Click on the highlighted region to filter.